Business Wire

Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the National Cancer Institute (NCI) has selected the company’s Shield™ ...

Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth

Guardant Health grows with Shield blood CRC screening, Quest deal, 50M reach, 335% surge, and FY25 revenue $981M up 33%. Read ...
Benzinga.com

Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue

On Tuesday, the Centers for Medicare & Medicaid Services (CMS) approved the Advanced Diagnostic Laboratory Test (ADLT) status for Guardant Health, Inc.’s (NASDAQ:GH) Shield blood test for colorectal ...
Business Wire

Guardant Health Wins Fast Company’s 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named ...
Hosted on MSN

Guardant Health announces Shield blood-based screening test results

Guardant Health (GH) “announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based screening test demonstrates patient adherence of 95% in ...
Seeking Alpha

Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States

Strategic partnership will expand Shield to PathGroup’s 15,000+ primary care and OBGYN physicians PathGroup’s extensive network of phlebotomists and Patient Service Centers enables easier access to ...